Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (25)
February 25, 2002
- Maurer's Healthcare Insight (20)
September 17, 2001
- Maurer's Healthcare Insight (19)
September 3, 2001
- Maurer's Healthcare Insight(18)
August 6, 2001
- Maurer's Healthcare Insight (17)
July 16, 2001
- Maurer's Healthcare Insight (16)
June 25, 2001
- Maurer's Healthcare Insight (15)
May 21, 2001
- Maurer's Healthcare Insight (14)
April 23, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight (12)
March 5, 2001
- 2001: A Bridge to the Future
January 1, 2001
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…